- Mithra is eligible for a downpayment of EUR 1.5 million
- 20-year exclusive license and supply agreement to generate annual recurring revenues and royalty payments
- Production at the Mithra CDMO facility
- Deal forms part of Mithra’s strategy to realise the full potential of the pipeline programs through global partnerships with leaders in Women’s Health
Liège, Belgium, 30 October 2018 – Mithra (Euronext Brussels: MITRA) today announced that it has entered into an exclusive license and supply agreement with Adcock Ingram to commercialize Estelle®, a combined oral contraceptive (COC), containing 15 mg Estetrol (E4) / 3 mg drospirenone (DRSP), in Southern Africa1. The product is a novel combined oral contraceptive with natural, native estrogen acting selectively in tissues combined with DRSP’s non-contraceptive benefits.